75 Shoreway Road, Suite D
About Alkahest, Inc.
At Alkahest, we strive to lead the way towards effective therapies for patients suffering from diseases associated with the detrimental processes of aging. We believe that as an industry, we simply haven’t done enough to help drive solutions for the most under-treated and devastating diseases affecting this growing demographic. We want to help.
Aging is the dominant risk factor in degenerative diseases. Many of the pressing age-related and neurodegenerative diseases have a profound impact on patients and their caregivers, yet have very limited treatment options. Alkahest has embarked upon a simple but elegant approach to treat disorders of aging by capitalizing on the body’s own natural regulatory and communication mechanisms, leveraging the plasma proteome. The promise of this science, and the potential to make a difference to patients around the world, was the founding principle of Alkahest.
For all of the great progress we have made so far, we credit our dedicated and impassioned team for driving our successes. Our culture is warm and supportive, genuine and ethical, rigorous and scientific, and collaborative yet entrepreneurial. Based in Silicon Valley, home to many leaders in the biotechnology industry, the heart of our culture is scientific innovation. We work hard, yet we have fun while we’re doing so. We are passionate about both our collegial atmosphere as well as working together on cutting-edge therapies that will change the lives of patients. We know we have a lot further to go, and we’re ready for the long haul.
43 articles about Alkahest, Inc.
Every week brings news of clinical trials, ranging from launches, first-patient dosing, full enrollment, interim data or final data. Here’s a look at some of the clinical trial news from last week.
BioSpace Movers and Shakers, July 26
7/26/2019Biotech and pharma companies bolster their executive leadership and boards of directors with this week's appointments.
Alkahest Presents Positive Results from Phase 2a Open Label Study of AKST4290 in Treatment-Naïve neovascular AMD at Retina World Congress
Alkahest, Inc., a clinical stage biotechnology company focused on developing transformative therapies to treat age-related diseases, shared results yesterday from its open label study, ALK4290-201.
Alkahest Doses First Subject in Phase 2 Clinical Trial of Lead Candidate in Patients with Severe Alzheimer's Disease
Alkahest, Inc. announced the dosing of the first subject with severe Alzheimer's disease in a Phase 2 clinical trial of GRF6019 in collaboration with development partner Grifols.
Alkahest to Present Results from Phase 2a Open Label Study of AKST4290 in wet AMD at Retina World Congress
Alkahest, Inc. will present the results from its open label study evaluating AKST4290 for the treatment of wet age-related macular degeneration in treatment-naïve patients at the Retina World Congress in Fort Lauderdale, Florida on March 24, 2019 at 11:33 a.m. EST.
Alkahest Announces Positive Top-Line Data from Two Phase 2a Studies of AKST4290 in Individuals with Wet Age-Related Macular Degeneration
Both treatment naïve and treatment refractory individuals experienced improved visual acuity
Alkahest Doses First Subject in Phase 2 Clinical Trial of GRF6021 in Patients with Parkinson's Disease and Cognitive Impairment
Grant funding by The Michael J. Fox Foundation will support Phase 2 trial
BioSpace Movers and Shakers: Nov. 26
11/26/2018In a short week leading up to Thanksgiving, several companies made leadership changes as they eye the coming year. We round up who made power moves this past week.
BioSpace Movers and Shakers Nov. 12
11/12/2018Biopharma companies name new members of their leadership teams. Who made big moves this week?
Alkahest Appoints Elizabeth Jeffords as Chief Commercial and Strategy Officer
Alkahest, Inc. today announced the appointment of Elizabeth Jeffords as chief commercial and strategy officer.
Alkahest to Present at the Society for Neuroscience 48th Annual Meeting
Presentations highlight a novel multifactorial approach to treating neurodegenerative diseases
Alkahest Scientific Founder Tony Wyss-Coray Recognized as One of TIME Magazine's 50 Most Influential People in Health Care
Alkahest Inc. announced today that Tony Wyss-Coray Ph.D., Alkahest's co-founder and board member was named to TIME Health's list of individuals who were most influential in transforming healthcare in 2018.
Alkahest Presentation at Clinical Trials in Alzheimer's Disease (CTAD) Conference October 26, 2018, Barcelona, Spain
Alkahest provided update on their novel multifactorial approach to the treatment of Alzheimer's Disease
19 (at Least!) of TIME Magazine’s 50 Most Influential Healthcare People Have Biopharma Ties
10/19/2018TIME Magazine came out with a list of the 50 most influential people in healthcare, dubbed The Health Care 50. A look through the list shows just how many ties and connections—as well as influence—this group has on the biopharma industry.
Alkahest, Inc. Announces Key Appointment of Bruce Morimoto, PhD
Bruce Morimoto joins Alkahest as Vice President, Drug Development Operations
Alkahest to Present at Alzheimer's Association International Conference (AAIC) Annual Meeting July 22-26, 2018 Chicago, IL
Presentations highlight a novel multifactorial approach to the treatment of Alzheimer's Disease
Alkahest, Inc. Announces Key Appointment
Michael Byrnes joins Alkahest as Chief Financial Officer
Alkahest Receives Grant from Michael J. Fox Foundation; Funding Will Support Preclinical Evaluation of ALK4290 for Parkinson's Disease
Alkahest, Inc. ("Alkahest"), a clinical-stage biotechnology company focused on developing innovative therapies to treat age-related diseases, today announced that it has been awarded a grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) entitled "Development of ALK4290 as a novel PD therapeutic" under the Principal Investigator S. Sakura Minami, Ph.D.
Alkahest Announces Initiation of Two Phase 2 Clinical Trials of ALK4290 in Age-Related Macular Degeneration
Alkahest Inc. is a clinical-stage biotechnology company focused on developing innovative therapies to treat age-related diseases
Alkahest Announces Initiation of Phase 2 Clinical Trial of GRF6019 in Alzheimer's Disease
Alkahest Inc. announced the initiation of a Phase 2 randomized, double-blinded dose response study of GRF6019 in patients with mild to moderate Alzheimer's Disease (ALK6019-201).